Presentations by Rutgers Cancer Institute of New Jersey Faculty Members at the 2019 American Society of Hematology Annual Meeting

Saturday, December 7, 2019

7:30 am – 11:00 am

19 Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma (Oral Presentation)
Author: Andrew M Evens, DO, MSc
Session: 621
Location: W230, Level 2 (Orange County Convention Center)

2:00 pm

235 Brief Pembrolizumab(PEM) Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients with Classical Hodgkin Lymphoma (cHL): A Multicenter Phase 2 PET-Adapted Study of Sequential PEM and AVD (Oral Presentation)
Author: Andrew M Evens, DO, MSc
Session: 624
Location: W224, Level 2 (Orange County Convention Center)

2:00 pm – 3:30 pm

Hodgkin Lymphoma: Celebrating 200 Years Since Thomas Hodgkin Entered Medicine (Oral Presentation)
Presenter: Andrew M Evens, DO, MSc
Program: Education Program
Location: Tangerine 2 (WF2), Level 2 (Orange County Convention Center)

5:30 pm – 7:30 pm

1130 Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial (Poster Presentation)
Author: Claire S. Philipp, MD, (Rutgers Robert Wood Johnson Medical School, New Brunswick)
Session: 322
Location: Hall B, Level 2 (Orange County Convention Center)
1327 Hispanic Race Is Associated with Increased Risk of Severe Sepsis in 1913 Hospitalizations of Children with AML and Infection (Poster Presentation)
Lead author: Beth Savage, PhD, CPNP, CPON (Rutgers School of Nursing)
Author: Peter D. Cole, MD
Location: Hall B, Level 2 (Orange County Convention Center)
Session: 613

1445 Deep DNA Sequencing Identifies Small Mutations in Patients with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Analysis of Intratumor Genomic Heterogeneity for Prediction of Disease Relapse (Poster Presentation)
Lead author: Athena Kritharis, MD
Authors: Sukhdeep Kaur, MD, (Rutgers Robert Wood Johnson Medical School, New Brunswick); Jui Wan Loh, BS, Mohammad Hadigol, PhD, Hossein Khiabanian, PhD and Roger Strair, MD, PhD
Location: Hall B, Level 2 (Orange County Convention Center)

1511 Transcriptomic and Metabolomic Profiling Identifies Calcium-Dependent Signaling Mechanisms As a Novel and Exploitable Target to Overcome Anti-CD20 Resistance in Non-Hodgkin Lymphoma (NHL) (Poster Presentation)
Senior Author: Andrew M. Evens, DO, MSc
Location: Hall B, Level 2 (Orange County Convention Center)

1541 A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404 (Poster Presentation)
Author: Kevin David, MD
Location: Hall B, Level 2 (Orange County Convention Center)

1563 Treatment with Full Chemotherapy Regimens in Older Adults with Hodgkin Lymphoma Improves 3-Year Overall Survival, but Less Than Half Receive Full Regimens (Poster Presentation)
Author: Andrew M. Evens, DO, MSc
Location: Hall B, Level 2 (Orange County Convention Center)

1573 Identification of FASN-Dependent Onco-Metabolic Regulation of the Pentose Phosphate Pathway (PPP) and Nucleotide Metabolism in Non-Hodgkin Lymphoma (NHL) (Poster Presentation)
Senior Author: Andrew M. Evens, DO, MSc
Location: Hall B, Level 2 (Orange County Convention Center)
1756 Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies (Poster Presentation)
Author: Rajat Bannerji, MD, PhD
Session: 642
Location: Hall B, Level 2 (Orange County Convention Center)

2134 Shared Decision Making in Cancer Treatment: Findings from a Large Survey of Lymphoma (LYM) Patients and Survivors (Poster Presentation)
Senior Author: Andrew M. Evens, DO, MSc
Session: 902
Location: Hall B, Level 2 (Orange County Convention Center)

Sunday, December 8, 2019
8:00 am

351 A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas (Oral Presentation)
Senior Author: Andrew M Evens, DO, MSc
Session: 626
Location: Hall E2, Level 2 (Orange County Convention Center)

9:30 am

397 The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC) (Oral Presentation)
Senior Author: Andrew M Evens, DO, MSc
Session: 627
Location: W224, Level 2 (Orange County Convention Center)

10:45 am

402 Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis (Oral Presentation)
Authors: Andrew M Evens, DO, MSc, and Kevin David, MD
Session: 627
Location: W224, Level 2 (Orange County Convention Center)
2288 Assessing Efficacy of Provider and Family Education, Electronic Health Record Documentation Tools, and Information Technology to Increase Use of Hydroxyurea in Children with Sickle Cell Anemia (Poster Presentation)
Author: Meenakshi Goyal-Khemka, MD
Session: 114
Location: Hall B, Level 2 (Orange County Convention Center)

2298 Prenatal Hemoglobinopathy Screening Practices: Areas for Improvement (Poster Presentation)
Lead author: Scott Moerdler, MD
Session: 114
Location: Hall B, Level 2 (Orange County Convention Center)

2371 Utility and Pitfalls of Stepwise Laboratory Testing for Heparin Induced Thrombocytopenia: Retrospective Review from an Academic Medical Center (Poster Presentation)
Lead author: Joshua Kra
Session: 311
Location: Hall B, Level 2 (Orange County Convention Center)

3048 Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study (Poster Presentation)
Author: Rajat Bannerji, MD, PhD
Session: 642
Location: Hall B, Level 2 (Orange County Convention Center)

3176 Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (Poster Presentation)
Lead Author: Dennis Cooper, MD
Session: 653
Location: Hall B, Level 2 (Orange County Convention Center)

3209 Vaccination Against Poly-N-Acetylglucosamine Decreases Neutrophil Activation and Gvhd While Maintaining Microbial Diversity (Poster Presentation)
Author: Zhan Ghao, (Rutgers Center for Advanced Biotechnology and Medicine, New Brunswick)
Session: 70
Location: Hall B, Level 2 (Orange County Convention Center)

3316 Evomela® Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation (Poster Presentation)
Lead Author: Marshall McKenna, MD, (Rutgers New Jersey Medical School, Newark)
Session: 731
Location: Hall B, Level 2 (Orange County Convention Center)
3384 Use of a Electronic Sickle Cell Dashboard to Improve Annual Transcranial Doppler Ultrasound (TCD) Completion Rates (Poster Presentation)
Author: Meenakshi Goyal-Khemka, MD
Session: 901
Location: Hall B, Level 2 (Orange County Convention Center)

Monday, December 9, 2019

7:00 am – 8:30 am

Hodgkin Lymphoma: Celebrating 200 Years Since Thomas Hodgkin Entered Medicine (Oral Presentation)
Presenter: Andrew M Evens, DO, MSc
Program: Education Program
Location: Tangerine 3 (WF3-4), Level 2 (Orange County Convention Center)

7:30 am

585 T-Cell Derived Interferon Gamma Directly Targets Intestinal Epithelium to Induce Stem Cell Apoptosis in GI Gvhd (Oral Presentation)
Author: Chen Liu, MD, PhD, (Rutgers New Jersey Medical School, Newark)
Session: 701
Location: W315, Level 3 (Orange County Convention Center)

3:00 pm

728 Post-Translational Mechanisms of NT5C2 Activation As Non-Genetic Drivers of Chemotherapy Resistance in Relapsed Acute Lymphoblastic Leukemia (Oral Presentation)
Author: Hossein Khiabanian, PhD
Session: 603
Location: W314, Level 3 (Orange County Convention Center)

4:00 pm

762 Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL) (Oral Presentation)
Lead Author: Rajat Bannerji, MD, PhD
Session: 626
Location: W304ABCD, Level 3 (Orange County Convention Center)
806 Glutaminase Inhibition Overcomes Acquired Resistance to Mitochondrial Complex I in NOTCH1-Driven T-Cell Acute Lymphoblastic Leukemias (T-ALL) Via Block of Glutamine Driven Reductive Metabolism
(Oral Presentation)
Author: Daniel Herranz Benito, PhD
Session: 605
Location: W304ABCD, Level 3 (Orange County Convention Center)

3720 High Burden of Clonal Hematopoiesis in First Responders Exposed to the World Trade Center Disaster (Poster Presentation)
Author: Advaitha Madireddy, PhD
Session: 503
Location: Hall B, Level 2 (Orange County Convention Center)

3779 S-Phase Progression of North American ATLL Cells Is Critically Regulated By the Proto-Oncogene BCL6 and Targetable By PARP Inhibition (Poster Presentation)
Author: Advaitha Madireddy, PhD
Session: 602
Location: Hall B, Level 2 (Orange County Convention Center)

3811 Genetic Ancestry and Skeletal Toxicities Among Childhood Acute Lymphoblastic Leukemia Patients in the DFCI 05-001 Cohort (Poster Presentation)
Author: Peter D. Cole, MD
Session: 612
Location: Hall B, Level 2 (Orange County Convention Center)

4007 A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL) (Poster Presentation)
Senior Author: Rajat Bannerji, MD, PhD
Session: 623
Location: Hall B, Level 2 (Orange County Convention Center)

4027 Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis (Poster Presentation)
Authors: Andrew M Evens, DO, MSc and Kevin David, MD
Session: 624
Location: Hall B, Level 2 (Orange County Convention Center)
4028 Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malignancy (Poster Presentation)
Lead author: Kevin David, MD
Session: 624
Location: Hall B, Level 2 (Orange County Convention Center)

4077 Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma (Poster Presentation)
Author: Kevin David, MD
Session: 626
Location: Hall B, Level 2 (Orange County Convention Center)

4379 Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans (Poster Presentation)
Author: Antoinette Stroup, PhD, (New Jersey State Cancer Registry and Rutgers School of Public Health)
Session: 651
Location: Hall B, Level 2 (Orange County Convention Center)

4485 Incorporation of Posttransplant Cyclophosphamide (PCy) As Part of Standard Immunophylaxis (IP) for All Allogeneic Transplants: A Retrospective, Single Institution Study (Poster Presentation)
Lead author: Dennis Cooper, MD
Authors: Jackie Manago, RN, BSN, Vimal Patel, MD, Dale Schaar, MD, PhD, Mary Kate McGrath, RN, APN, Anne Tyno, RN, MSN, APN-C and Roger Strair, MD, PhD
Session: 721
Location: Hall B, Level 2 (Orange County Convention Center)

4571 Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma (Poster Presentation)
Author: Kevin David, MD
Session: 731
Location: Hall B, Level 2 (Orange County Convention Center)

4726 Narcotic Use in Multiple Myeloma Patients at the Time of ASCT and One-Year Follow up (Poster Presentation)
Senior Author: Dennis Cooper, MD
Session: 902
Location: Hall B, Level 2 (Orange County Convention Center)